ACADIA Pharmaceuticals (ACAD) Receives a Hold from Goldman Sachs

Goldman Sachs analyst Salveen Richter maintained a Hold rating on ACADIA Pharmaceuticals (ACADResearch Report) today and set a price target of $24.00. The company’s shares closed last Monday at $24.37.

According to TipRanks.com, Richter is a 5-star analyst with an average return of 31.4% and a 52.2% success rate. Richter covers the Healthcare sector, focusing on stocks such as Crispr Therapeutics AG, Reata Pharmaceuticals, and Allogene Therapeutics.

The word on The Street in general, suggests a Moderate Buy analyst consensus rating for ACADIA Pharmaceuticals with a $29.77 average price target, which is a 24.5% upside from current levels. In a report issued on February 25, Needham also maintained a Hold rating on the stock.

See today’s best-performing stocks on TipRanks >>

ACADIA Pharmaceuticals’ market cap is currently $3.86B and has a P/E ratio of -22.97.

Based on the recent corporate insider activity of 18 insiders, corporate insider sentiment is negative on the stock. This means that over the past quarter there has been an increase of insiders selling their shares of ACAD in relation to earlier this year.

TipRanks has tracked 36,000 company insiders and found that a few of them are better than others when it comes to timing their transactions. See which 3 stocks are most likely to make moves following their insider activities.

ACADIA Pharmaceuticals, Inc. operates as a biopharmaceutical company focused on the development and commercialization of medicines to address unmet medical needs in central nervous system, or CNS, disorders. The firms product include Nuplazid, which is used for the treatment of hallucinations and delusions associated with Parkinson’s disease psychosis. The company was founded by Mark R. Brann on July 16, 1993 and is headquartered in San Diego, CA.

Read More on ACAD:

Tired of arriving late to the Big Returns Party?​
Most investors don’t have major gainers like TSLA or NVDA on their radar from the start.
The profusion of opinions on social media and financial blogs makes it impossible to distinguish between real growth potential and pure hype.
​​For the past decade, we have developed and perfected technology designed to help private investors, just like you, find the best opportunities, with the greatest upside potential, in any financial climate.​
Learn More

Latest News Feed